Clinical Trial

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II study to evaluate the efficacy and safety of PM8002 in combination with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed to EGFR-TKI treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-02-23; most recent amendment 2025-03-31.
Status change: Recruiting → Active, Not Recruiting 2024-08-08
Status change: Not Yet Recruiting → Recruiting 2023-07-12
Trial Details
NCT Number NCT05756972
Lead Sponsor Biotheus Inc.
Conditions NSCLC
Enrollment 64 participants
Start Date 2023-06-26
Primary Completion 2024-09-13 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-03